Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2016

01-10-2016 | Original Article

Predictive factors associated with increased progression to dialysis in early chronic kidney disease (stage 1–3) patients

Authors: Nao Nohara, Hiroaki Io, Mayumi Matsumoto, Masako Furukawa, Kozue Okumura, Junichiro Nakata, Yoshio Shimizu, Satoshi Horikoshi, Yasuhiko Tomino

Published in: Clinical and Experimental Nephrology | Issue 5/2016

Login to get access

Abstract

Background

It has been reported that echocardiographic parameters are independently associated with the progression to dialysis in patients with chronic kidney disease (CKD) (stages 3–5). The objective of the present study was to evaluate whether physical, biochemical, and echocardiographic parameters are associated with the progression to dialysis in early CKD (stage 1–3) patients.

Methods

This retrospective study enrolled 272 CKD patients who underwent echocardiography at the time of diet education, renal biopsy, and the examination of kidney injuries at Juntendo University Hospital, Tokyo, Japan, from 2001 to 2010. All of these CKD patients were classified into stages 1–3. The study patients received regular follow-up at our outpatient clinic in our division. The renal end point was defined as commencement of dialysis.

Results

Patients with progression to dialysis were significantly associated with higher levels of left ventricular mass index (LVMI), urinary protein, systolic blood pressure, many kinds of anti-hypertensive drugs, and lower levels of albumin and hemoglobin. In a Cox proportional hazard regression analysis, LVMI [hazard ration (HR) 1.018; 95 % confidence interval (CI) 1.007–1.029; p = 0.002], urinary protein and hemoglobin were independently associated with factors for progression to dialysis in early CKD patients.

Conclusion

This study of patients in early CKD demonstrated that higher LVMI and urinary protein and that lower levels of hemoglobin in blood were associated with progression to dialysis. LVMI evaluated by echocardiography may identify a high risk of progression to dialysis in early CKD patients.
Literature
1.
go back to reference Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRefPubMed Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRefPubMed
2.
go back to reference Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol. 2009;4:S79–91.CrossRefPubMed Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol. 2009;4:S79–91.CrossRefPubMed
3.
go back to reference Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murrray DC, Barre PE. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186–92.CrossRefPubMed Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murrray DC, Barre PE. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186–92.CrossRefPubMed
4.
go back to reference Foley RN, Parfrey PS, Kent GM, Harnett JD, Murrray DC, Barre PE. Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int. 1998;54:1720–5.CrossRefPubMed Foley RN, Parfrey PS, Kent GM, Harnett JD, Murrray DC, Barre PE. Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int. 1998;54:1720–5.CrossRefPubMed
5.
go back to reference Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ. 2010;341:c4986.CrossRefPubMedPubMedCentral Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ. 2010;341:c4986.CrossRefPubMedPubMedCentral
6.
go back to reference Chen SC, Su HM, Hung CC, Chang JM, Liu WC, Tsai JC, Lin MY, Hwang SJ, Chen HC. Echocardiographic parameters are independently associated with rate of renal function decline and progression to dialysis in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:2750–8.CrossRefPubMedPubMedCentral Chen SC, Su HM, Hung CC, Chang JM, Liu WC, Tsai JC, Lin MY, Hwang SJ, Chen HC. Echocardiographic parameters are independently associated with rate of renal function decline and progression to dialysis in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:2750–8.CrossRefPubMedPubMedCentral
7.
go back to reference Io H, Matsumoto M, Okumura K, Sato M, Masuda A, Furukawa M, Nohara N, Tanimoto M, Kodama F, Hagiwara S, Gohda T, Shimizu Y, Tomoino Y. Predictive factors associated with left ventricular hypertrophy at baseline and in the follow-up period in non-diabetic hemodialysis patients. Semin Dial. 2011;24(3):349–54.CrossRefPubMed Io H, Matsumoto M, Okumura K, Sato M, Masuda A, Furukawa M, Nohara N, Tanimoto M, Kodama F, Hagiwara S, Gohda T, Shimizu Y, Tomoino Y. Predictive factors associated with left ventricular hypertrophy at baseline and in the follow-up period in non-diabetic hemodialysis patients. Semin Dial. 2011;24(3):349–54.CrossRefPubMed
8.
go back to reference National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(Suppl 1):S1–266. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(Suppl 1):S1–266.
9.
go back to reference Management of Arterial Hypertension of the European Society of Hypertension, European Society of Cardiology. Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;2007(25):1105–87. Management of Arterial Hypertension of the European Society of Hypertension, European Society of Cardiology. Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;2007(25):1105–87.
10.
go back to reference Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ, Chamber Quantification Writing Group, American Society of Echocardiography’s Guidelines and Standards Committee, European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Camber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440–63.CrossRefPubMed Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ, Chamber Quantification Writing Group, American Society of Echocardiography’s Guidelines and Standards Committee, European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Camber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440–63.CrossRefPubMed
11.
go back to reference Harnett JD, Murphy B, Collingwood P, Purchase L, Kent G, Parfrey PS. The reliability and validity of echocardiographic measurement of left ventricular mass index in hemodialysis patients. Nephron. 1993;65:212–4.CrossRefPubMed Harnett JD, Murphy B, Collingwood P, Purchase L, Kent G, Parfrey PS. The reliability and validity of echocardiographic measurement of left ventricular mass index in hemodialysis patients. Nephron. 1993;65:212–4.CrossRefPubMed
12.
go back to reference Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet. 2000;356:147–52.CrossRefPubMed Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet. 2000;356:147–52.CrossRefPubMed
13.
go back to reference Hage FG, Venkataraman R, Zoghbi GJ, Perry GJ, DeMattos AM, Iskandrian AE. The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol. 2009;53:2129–40.CrossRefPubMed Hage FG, Venkataraman R, Zoghbi GJ, Perry GJ, DeMattos AM, Iskandrian AE. The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol. 2009;53:2129–40.CrossRefPubMed
14.
go back to reference Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis. 2005;46:320–7.CrossRefPubMed Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis. 2005;46:320–7.CrossRefPubMed
15.
go back to reference Stewart GA, Gansevoort RT, Mark PB, Rooney E, McDonagh TA, Dargie HJ, Stuart R, Rodger C, Jardine AG. Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int. 2005;67:217–26.CrossRefPubMed Stewart GA, Gansevoort RT, Mark PB, Rooney E, McDonagh TA, Dargie HJ, Stuart R, Rodger C, Jardine AG. Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int. 2005;67:217–26.CrossRefPubMed
16.
go back to reference Locatelli F, Bommer J, London GM, Martin-Malo A, Wanner C, Yaqoob M, Zoccali C. Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. Nephrol Dial Transplant. 2001;16:459–68.CrossRefPubMed Locatelli F, Bommer J, London GM, Martin-Malo A, Wanner C, Yaqoob M, Zoccali C. Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. Nephrol Dial Transplant. 2001;16:459–68.CrossRefPubMed
17.
go back to reference Io H, Ro Y, Sekiguchi Y, Shimaoka T, Inuma J, Hotta Y, Aruga S, Inami Y, Sato M, Kobayashi T, Masuda A, Kaneko K, Hamada C, Ohtaki E, Horikoshi S, Tomino Y. Cardiac function and structure in longitudinal analysis of echocardiography in peritoneal dialysis patients. Perit Dial Int. 2010;30:353–61.CrossRefPubMed Io H, Ro Y, Sekiguchi Y, Shimaoka T, Inuma J, Hotta Y, Aruga S, Inami Y, Sato M, Kobayashi T, Masuda A, Kaneko K, Hamada C, Ohtaki E, Horikoshi S, Tomino Y. Cardiac function and structure in longitudinal analysis of echocardiography in peritoneal dialysis patients. Perit Dial Int. 2010;30:353–61.CrossRefPubMed
18.
go back to reference Matsumoto M, Io H, Furukawa M, Okumura K, Masuda A, Seto T, Takagi M, Sato M, Nagahama L, Omote K, Hisada A, Horikoshi S, Tomino Y. Risk factors associated with increased left ventricular mass index in chronic kidney disease patients evaluated using echocardiography. J Nephrol. 2012;25(05):794–801.CrossRefPubMed Matsumoto M, Io H, Furukawa M, Okumura K, Masuda A, Seto T, Takagi M, Sato M, Nagahama L, Omote K, Hisada A, Horikoshi S, Tomino Y. Risk factors associated with increased left ventricular mass index in chronic kidney disease patients evaluated using echocardiography. J Nephrol. 2012;25(05):794–801.CrossRefPubMed
19.
go back to reference Nitta K. Pathogenesis and therapeutic implications of cardiorenal syndrome. Clin Exp Nephrol. 2011;15:187–94.CrossRefPubMed Nitta K. Pathogenesis and therapeutic implications of cardiorenal syndrome. Clin Exp Nephrol. 2011;15:187–94.CrossRefPubMed
20.
go back to reference Paoletti E, Bellino D, Gallina AM, Amidone M, Cassottana P, Cannella G. Is left ventricular hypertrophy a powerful predictor of progression to dialysis in chronic kidney disease? Nephrol Dial Transplant. 2011;26:670–7.CrossRefPubMed Paoletti E, Bellino D, Gallina AM, Amidone M, Cassottana P, Cannella G. Is left ventricular hypertrophy a powerful predictor of progression to dialysis in chronic kidney disease? Nephrol Dial Transplant. 2011;26:670–7.CrossRefPubMed
21.
go back to reference Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330:877–84.CrossRefPubMed Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330:877–84.CrossRefPubMed
22.
go back to reference Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seiffer JL. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754–62.CrossRefPubMed Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seiffer JL. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754–62.CrossRefPubMed
23.
go back to reference Bansal N, Tighiouart H, Weiner D, Griffith J, Vlagopoulos P, Salem D, Levin A, Sarnak MJ. Anemia as a risk factor for kidney function decline in individuals with heart failure. Am J Cardiol. 2007;99:1137–42.CrossRefPubMed Bansal N, Tighiouart H, Weiner D, Griffith J, Vlagopoulos P, Salem D, Levin A, Sarnak MJ. Anemia as a risk factor for kidney function decline in individuals with heart failure. Am J Cardiol. 2007;99:1137–42.CrossRefPubMed
24.
go back to reference Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R, RENAAL Study Investigators. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003;63:1499–507.CrossRefPubMed Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R, RENAAL Study Investigators. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003;63:1499–507.CrossRefPubMed
25.
go back to reference Fine LG, Bandyopadhay D, Norman JT. Is there a common mechanism for the progression of difference types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int Suppl. 2000;75:S22–6.CrossRefPubMed Fine LG, Bandyopadhay D, Norman JT. Is there a common mechanism for the progression of difference types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int Suppl. 2000;75:S22–6.CrossRefPubMed
26.
go back to reference Nangaku M. Hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. Nephron Exp Nephrol. 2004;98:e8–12.CrossRefPubMed Nangaku M. Hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. Nephron Exp Nephrol. 2004;98:e8–12.CrossRefPubMed
27.
go back to reference Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–98.CrossRefPubMed Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–98.CrossRefPubMed
28.
go back to reference Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–84.CrossRefPubMed Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–84.CrossRefPubMed
29.
go back to reference Collins AJ. Anemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol Dial Transplant. 2003;18(Suppl 2):ii2–6.PubMed Collins AJ. Anemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol Dial Transplant. 2003;18(Suppl 2):ii2–6.PubMed
30.
go back to reference Okumura K, Io H, Matsumoto M, Seto T, Takagi M, Masuda A, Furukawa M, Nagahama L, Omote K, Hisada A, Hamada C, Horikoshi S, Tomino Y. Predictive factors associated with change rates of LV hypertrophy and renal dysfunction in CKD patients. Clin Nephrol. 2013;79:7–14.CrossRefPubMed Okumura K, Io H, Matsumoto M, Seto T, Takagi M, Masuda A, Furukawa M, Nagahama L, Omote K, Hisada A, Hamada C, Horikoshi S, Tomino Y. Predictive factors associated with change rates of LV hypertrophy and renal dysfunction in CKD patients. Clin Nephrol. 2013;79:7–14.CrossRefPubMed
Metadata
Title
Predictive factors associated with increased progression to dialysis in early chronic kidney disease (stage 1–3) patients
Authors
Nao Nohara
Hiroaki Io
Mayumi Matsumoto
Masako Furukawa
Kozue Okumura
Junichiro Nakata
Yoshio Shimizu
Satoshi Horikoshi
Yasuhiko Tomino
Publication date
01-10-2016
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2016
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-015-1210-3

Other articles of this Issue 5/2016

Clinical and Experimental Nephrology 5/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.